Travere Therapeutics, Inc. (TVTX)
Health Care ยท Pharmaceutical Preparations
Travere Therapeutics, Inc. (TVTX) is listed on Nasdaq, where its shares have traded since July 23, 2003. SentiSense covers Travere Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Eric Dube is its chief executive officer. The company reports 497 employees, and its corporate website is www.travere.com.
About Travere Therapeutics, Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Latest reported results
Travere Therapeutics Inc. reported revenue of $224.6 million for Q3 FY2026, up 36.2% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 307 institutions reported holding TVTX, with 104.9 million shares worth $6.0 billion in aggregate. The largest reported holders were Janus Henderson (Jupiter Topco), BlackRock and FMR. Of the 5 largest reported holders, 2 added shares and 3 reduced their positions during the quarter.
More on TVTX
- TVTX sentiment: whether news and social coverage of Travere Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- TVTX ownership: all 307 reporting institutions, plus insider and congressional trades.
- TVTX financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Travere Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Travere Therapeutics, Inc. do?
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases.
What sector is TVTX in?
SentiSense classifies Travere Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does TVTX stock trade?
Travere Therapeutics, Inc. (TVTX) is listed on Nasdaq, where its shares have traded since July 23, 2003.
Who is the CEO of Travere Therapeutics, Inc.?
Eric Dube is the chief executive officer of Travere Therapeutics, Inc..